Carbamazepine Label Gets Warning for Asian Patients

By Kirn, Timothy F. | Clinical Psychiatry News, March 2008 | Go to article overview
Save to active project

Carbamazepine Label Gets Warning for Asian Patients


Kirn, Timothy F., Clinical Psychiatry News


Patients of Asian ancestry are at significantly increased risk for fatal skin reactions when treated with carbamazepine and should first undergo genetic testing to assess their risk before initiating therapy, according to an alert issued by the Food and Drug Administration.

People found to carry the human leukocyte antigen--B*1502 allele should forgo treatment with carbamazepine, unless the expected benefit clearly outweighs the risk, according to the FDA's alert. The fatal skin reactions, which include Stevens-Johnson syndrome and toxic epidermal necrolysis, occur more commonly in patients with the human leukocyte antigen--B*1502 allele. People with ancestry across broad areas of Asia, including South Asian Indians, account for almost all carriers of this allele.

The test for the allele is commercially available.

The prevalence of the HLA-B*1502 allele may be 10%-15% of the populations of China, Taiwan, Thailand, Malaysia, Indonesia, and the Philippines. In South Asia, including India, the prevalence is thought to be 2%-4%, according to a new boxed warning added to carbamazepine labeling.

The prevalence of the allele in patients of Japanese and Korean descent is thought to be less than 1%.

Overall, the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis associated with carbamazepine use is thought to be 1 patient to 6 patients per 10,000 users in countries with a primarily white population. However, the rate may be 10 times higher in Asian countries, according to the FDA.

One case-control study from Taiwan reported that 59 of 60 patients who developed Stevens-Johnson syndrome or toxic epidermal necrolysis associated with carbamazepine had the allele. That compared with a 4% incidence of the allele in patients who tolerated carbamazepine. The findings suggested an absolute risk of 5% in persons positive for the allele (Pharmacogenet.

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
Loading One moment ...
Project items
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited article

Carbamazepine Label Gets Warning for Asian Patients
Settings

Settings

Typeface
Text size Smaller Larger
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

While we understand printed pages are helpful to our users, this limitation is necessary to help protect our publishers' copyrighted material and prevent its unlawful distribution. We are sorry for any inconvenience.
Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.

Are you sure you want to delete this highlight?